Indaptus Therapeutics, Inc.
INDP
$2.55
$0.5325.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.21% | 29.30% | -19.77% | -16.77% | -11.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.91% | 29.08% | 3.09% | -0.83% | 0.81% |
| Operating Income | -8.91% | -29.08% | -3.09% | 0.83% | -0.81% |
| Income Before Tax | -19.75% | -38.79% | -13.25% | -7.71% | -5.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.75% | -38.79% | -13.25% | -7.71% | -5.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.75% | -38.79% | -13.25% | -7.71% | -5.15% |
| EBIT | -8.91% | -29.08% | -3.09% | 0.83% | -0.81% |
| EBITDA | 4.59% | -29.08% | -3.10% | 0.83% | -0.82% |
| EPS Basic | 59.83% | 43.40% | 34.03% | 27.54% | 15.98% |
| Normalized Basic EPS | 59.83% | 43.40% | 34.03% | 27.54% | 15.98% |
| EPS Diluted | 59.83% | 43.40% | 34.03% | 27.54% | 15.98% |
| Normalized Diluted EPS | 59.83% | 43.40% | 34.03% | 27.54% | 15.98% |
| Average Basic Shares Outstanding | 834.60% | 189.32% | 97.38% | 49.39% | 27.57% |
| Average Diluted Shares Outstanding | 834.60% | 189.32% | 97.38% | 49.39% | 27.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |